Table of Content

"1    INTRODUCTION    29
1.1    OBJECTIVES OF THE STUDY    29
1.2    MARKET DEFINITION    29
1.2.1    INCLUSIONS AND EXCLUSIONS    30
1.3    MARKET SCOPE    31
1.3.1    MARKETS COVERED    31
1.3.2    MARKETS COVERED–BY REGION    31
1.3.3    YEARS CONSIDERED FOR THE STUDY    32
1.4    CURRENCY    32
TABLE 1    EXCHANGE RATES UTILIZED FOR CONVERSION TO USD    32
1.5    STAKEHOLDERS    33
1.6    SUMMARY OF CHANGES    33
2    RESEARCH METHODOLOGY    35
2.1    RESEARCH APPROACH    35
FIGURE 1    RESEARCH DESIGN    35
2.1.1    SECONDARY DATA    36
2.1.1.1    Key data from secondary sources    37
2.1.2    PRIMARY DATA    37
2.1.2.1    Primary sources    37
2.1.2.2    Key data from primary sources    38
2.1.2.3    Breakdown of primaries    39
FIGURE 2    BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION    39
2.2    MARKET SIZE ESTIMATION    39
FIGURE 3    MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020)    40
FIGURE 4    SUPPLY SIDE ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET    41
FIGURE 5    TOP-DOWN APPROACH    42
FIGURE 6    CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2021– 2026)    43
FIGURE 7    CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2020)    44
2.3    MARKET BREAKDOWN & DATA TRIANGULATION    45
FIGURE 8    DATA TRIANGULATION METHODOLOGY    45
2.4    KEY INDUSTRY INSIGHTS    46
2.5    LIMITATIONS    46
2.5.1    METHODOLOGY-RELATED LIMITATIONS    46
2.6    RISK ASSESSMENT    47
2.7    ASSUMPTIONS FOR THE STUDY    47
3    EXECUTIVE SUMMARY    48
FIGURE 9    NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION)    48
FIGURE 10    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION)    49
FIGURE 11    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION)    50
FIGURE 12    NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2021 VS. 2026 (USD MILLION)    50
FIGURE 13    NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION)    51
FIGURE 14    NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2021 VS. 2026 (USD MILLION)    52
FIGURE 15    GEOGRAPHICAL SNAPSHOT OF THE NEEDLE-FREE INJECTION
SYSTEM MARKET    53
4    PREMIUM INSIGHTS    54
4.1    NEEDLE-FREE INJECTION SYSTEM MARKET OVERVIEW    54
FIGURE 16    HIGH PREVALENCE OF INFECTIOUS DISEASES, GROWING INCIDENCE OF COMMUNICABLE DISEASES DUE TO NEEDLESTICK INJURIES, AND RISE IN DEMAND FOR SELF-INJECTION DEVICES TO DRIVE MARKET GROWTH    54
4.2    ASIA PACIFIC NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION AND COUNTRY    55
FIGURE 17    VACCINATION ACCOUNTED FOR THE LARGEST SHARE IN ASIA PACIFIC    55
4.3    NEEDLE-FREE INJECTION SYSTEM MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES    56
FIGURE 18    CHINA TO REGISTER HIGHEST GROWTH RATES DURING
 THE FORECAST PERIOD    56
4.4    NEEDLE-FREE INJECTION SYSTEM MARKET: DEVELOPING VS DEVELOPED COUNTRIES    57
FIGURE 19    DEVELOPING COUNTRIES TO OFFER HIGHER GROWTH    57
4.5    REGIONAL MIX: NEEDLE-FREE INJECTION SYSTEM MARKET    57
FIGURE 20    APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD    57
5    MARKET OVERVIEW    58
5.1    INTRODUCTION    58
5.2    MARKET DYNAMICS: IMPACT ANALYSIS    58
5.2.1    DRIVERS    59
5.2.1.1    High prevalence of infectious diseases globally    59
FIGURE 21    PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE    60
TABLE 2    PREVALENCE OF HIV WORLDWIDE (2017 VS. 2020)    61
5.2.1.2    Increasing incidence of communicable diseases due to needlestick injuries    62
5.2.1.3    Rise in demand for self-injection devices    62
5.2.1.4    Increased number of technological advancements    62
5.2.1.5    Reduction in injection system costs    63

5.2.2    RESTRAINTS    63
5.2.2.1    Higher cost of development as compared to conventional injection systems    63
5.2.2.2    Limitation with large volume and intravenous administration systems    64
5.2.3    OPPORTUNITIES    64
5.2.3.1    Rising demand for biosimilars and vaccination processes    64
5.2.3.2    Increasing number of emerging markets    64
5.2.4    CHALLENGES    65
5.2.4.1    Rise in need to ensure system sterility    65
5.2.4.2    Growth in alternative modes of drug delivery    65
5.3    ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN NEEDLE-FREE INJECTION SYSTEM MARKET    66
FIGURE 22    IMPACT OF COVID-19 PANDEMIC ON ENTIRE NEEDLE-FREE INJECTION ECOSYSTEM (2020)- KEY HOT SPOTS OF ACTIVITY ARE HIGHLIGHTED PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE    66
5.4    PRICING ANALYSIS    67
TABLE 3    AVERAGE SELLING PRICE OF NEEDLE-FREE INJECTORS IN NORTH AMERICA, BY APPLICATIONS, FOR 2020    67
5.5    SUPPLY CHAIN ANALYSIS    67
FIGURE 23    SUPPLY CHAIN ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET (2020)    68
5.6    PATENT ANALYSIS    69
5.6.1    PATENT PUBLICATION TRENDS FOR NEEDLE-FREE INJECTION
SYSTEM MARKET    69
FIGURE 24    GLOBAL PATENT PUBLICATION TRENDS IN NEEDLE-FREE INJECTION SYSTEM, 2016–2021    70
5.6.2    TOP APPLICANTS (COMPANIES) OF NEEDLE-FREE INJECTION SYSTEM PATENTS    70
FIGURE 25    TOP COMPANIES THAT APPLIED FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021    70
5.6.3    JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN NEEDLE-FREE INJECTION SYSTEM MARKET    71
FIGURE 26    JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021    71
5.7    VALUE CHAIN ANALYSIS    71
FIGURE 27    NEEDLE-FREE INJECTION SYSTEM MARKET: VALUE CHAIN ANALYSIS (2020)    72
5.8    TECHNOLOGY ANALYSIS    72
5.8.1    KEY TECHNOLOGY: JET-BASED NEEDLE-FREE INJECTORS    72
5.8.2    ADJACENT TECHNOLOGY: SPRING-BASED NEEDLE-FREE INJECTORS    72
5.8.3    MICROARRAY PATCH    72
5.8.4    OTHER TECHNOLOGIES    73
5.9    REGULATORY LANDSCAPE    73
TABLE 4    REGULATORY STANDARDS/APPROVALS REQUIRED FOR NEEDLE-FREE INJECTION PRODUCTS, BY COUNTRY/REGION    73

5.10    PORTER’S FIVE FORCES ANALYSIS    73
TABLE 5    NEEDLE-FREE INJECTION SYSTEM: PORTER’S FIVE FORCES ANALYSIS    73
5.10.1    THREAT FROM NEW ENTRANTS    74
5.10.2    COMPETITIVE RIVALRY    74
5.10.3    BARGAINING POWER OF BUYERS    75
5.10.4    BARGAINING POWER OF SUPPLIERS    75
5.10.5    THREAT FROM SUBSTITUTES    75
6    NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT    76
6.1    INTRODUCTION    77
TABLE 6    NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    77
6.2    FILLABLE NEEDLE-FREE INJECTORS    77
6.2.1    TREATMENT OF DISEASES THAT REQUIRE REGULAR ADMINISTRATION OF MEDICATION TO DRIVE MARKET GROWTH    77
TABLE 7    FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,
 2019–2026 (USD MILLION)    78
6.3    PREFILLED NEEDLE-FREE INJECTORS    79
6.3.1    SELF-ADMINISTRATION OF DRUGS FOR TREATMENT TO DRIVE
 MARKET GROWTH    79
TABLE 8    PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    79
7    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY    80
7.1    INTRODUCTION    81
TABLE 9    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    81
7.2    JET-BASED NEEDLE-FREE INJECTORS    82
7.2.1    WIDE APPLICATIONS OF JET-BASED INJECTIONS
 TO DRIVE SEGMENT GROWTH    82
TABLE 10    JET-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    82
7.3    SPRING-BASED NEEDLE-FREE INJECTORS    83
7.3.1    LOW COST OF SPRING-BASED INJECTORS TO DRIVE MARKET GROWTH    83
TABLE 11    SPRING-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    83
7.4    MICRO-ARRAY PATCH    84
7.4.1    FUTURE DEMAND FOR VACCINES AND CONTRACEPTIVES MICRO-ARRAY PATCHES TO DRIVE MARKET GROWTH    84
TABLE 12    MICRO-ARRAY PATCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    84
7.5    OTHER TECHNOLOGIES    85
TABLE 13    OTHER TECHNOLOGIES NEEDLE-FREE INJECTION SYSTEM MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)    85

8    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE    86
8.1    INTRODUCTION    87
TABLE 14    NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    87
8.2    LIQUID-BASED NEEDLE-FREE INJECTORS    87
8.2.1    INCREASE IN VACCINATION FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH    87
TABLE 15    LIQUID-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    88
8.3    POWDER-BASED NEEDLE-FREE INJECTORS    89
8.3.1    REQUIREMENT OF STABLE DRUGS TO DRIVE MARKET GROWTH    89
TABLE 16    POWDER-BASED NEEDLE FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    89
8.4    PROJECTILE/DEPOT-BASED NEEDLE-FREE INJECTORS    90
8.4.1    USE OF INERT MATERIAL OR SELF MEDICAMENT TO DRIVE MARKET GROWTH    90
TABLE 17    PROJECTILE/DEPOT-BASED NEEDLE FREE INJECTION SYSTEM MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)    90
9    NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY    91
9.1    INTRODUCTION    92
TABLE 18    NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2019–2026 (USD MILLION)    92
9.2    SUBCUTANEOUS NEEDLE-FREE INJECTORS    92
9.2.1    PREFERENCE FOR ADMINISTERING DELICATE DRUGS FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH    92
TABLE 19    SUBCUTANEOUS NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    93
9.2.2    INTRAMUSCULAR NEEDLE-FREE INJECTORS    93
9.2.2.1    Increase in vaccination requirement to drive market growth    93
TABLE 20    INTRAMUSCULAR NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    94
9.2.3    INTRADERMAL NEEDLE-FREE INJECTORS    94
9.2.3.1    Use of inert material or self medicament to drive market growth    94
TABLE 21    INTRADERMAL NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    95
10    NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION    96
10.1    INTRODUCTION    97
TABLE 22    NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    97
10.2    VACCINE DELIVERY    97
10.2.1    COST-EFFECTIVENESS AND RISE OF PREVENTIVE MEASURES TO DRIVE GROWTH IN VACCINES DELIVERY    97
TABLE 23    NEEDLE-FREE INJECTION SYSTEM MARKET FOR VACCINE DELIVERY,
BY COUNTRY,  2019–2026 (USD MILLION)    98

10.3    INSULIN DELIVERY    98
10.3.1    RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH    98
TABLE 24    NEEDLE-FREE INJECTION SYSTEM MARKET FOR INSULIN DELIVERY,
BY COUNTRY, 2019–2026 (USD MILLION)    99
10.4    ONCOLOGY    100
10.4.1    RISE IN CANCER PREVALENCE AND AVAILABILITY OF CANCER TREATMENT TO DRIVE MARKET GROWTH    100
TABLE 25    NEEDLE-FREE INJECTION SYSTEM MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)    100
10.5    PAIN MANAGEMENT    101
10.5.1    INCREASED PREVALENCE AND TREATMENT OF CHRONIC DISEASES TO DRIVE MARKET GROWTH    101
TABLE 26    NEEDLE-FREE INJECTION SYSTEM MARKET FOR PAIN MANAGEMENT,
BY COUNTRY, 2019–2026 (USD MILLION)    101
10.6    DERMATOLOGY    102
10.6.1    INCREASED DERMATOLOGY-BASED TREATMENTS AND SURGERIES TO DRIVE MARKET GROWTH    102
TABLE 27    NEEDLE-FREE INJECTION SYSTEM MARKET FOR DERMATOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION)    102
10.7    OTHER APPLICATIONS    103
TABLE 28    NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER APPLICATIONS,
 BY COUNTRY, 2019–2026 (USD MILLION)    103
11    NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER    104
11.1    INTRODUCTION    105
TABLE 29    NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    105
11.2    HOSPITALS & CLINICS    106
11.2.1    INCREASING USE OF NEEDLE-LESS VACCINATION TO DRIVE ADOPTION    106
TABLE 30    NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2019–2026 (USD MILLION)    106
11.3    HOMECARE SETTINGS    107
11.3.1    GROWING NEED FOR HOME SELF-ADMINISTRATION AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH    107
TABLE 31    NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOMECARE SETTINGS,
BY COUNTRY, 2019–2026 (USD MILLION)    107
11.4    RESEARCH LABORATORIES    108
11.4.1    GROWING RESEARCH OF DRUG TESTING ON ANIMALS TO DRIVE MARKET GROWTH    108
TABLE 32    NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)    108
11.5    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES    109
11.5.1    INCREASING FOCUS ON BIOLOGICS DELIVERY RESEARCH TO DRIVE USAGE    109
TABLE 33    NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)    109

11.6    OTHER END USERS    110
TABLE 34    NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION)    110
12    NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION    111
12.1    INTRODUCTION    112
FIGURE 28    US TO DOMINATE NEEDLE-FREE INJECTION SYSTEM MARKET DURING FORECAST PERIOD    112
TABLE 35    NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION,
2019–2026 (USD MILLION)    113
12.2    NORTH AMERICA    113
FIGURE 29    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT    114
TABLE 36    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    115
TABLE 37    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    115
TABLE 38    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
 BY TECHNOLOGY, 2019–2026 (USD MILLION)    115
TABLE 39    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)    116
TABLE 40    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    116
TABLE 41    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)    117
TABLE 42    NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)    117
12.2.1    US    118
12.2.1.1    US to account for the largest share of needle-free injection system market    118
TABLE 43    US: MACROECONOMIC INDICATORS    118
TABLE 44    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    119
TABLE 45    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    119
TABLE 46    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    119
TABLE 47    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
 2019–2026 (USD MILLION)    120
TABLE 48    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    120
TABLE 49    US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    121
12.2.2    CANADA    121
12.2.2.1    Availability of research funding and implementation of favorable government initiatives to drive market growth    121
TABLE 50    CANADA: MACROECONOMIC INDICATORS    122
TABLE 51    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
 2019–2026 (USD MILLION)    122
TABLE 52    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    123
TABLE 53    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    123
TABLE 54    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    124
TABLE 55    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)    124
TABLE 56    CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
 2019–2026 (USD MILLION)    125
12.3    EUROPE    125
FIGURE 30    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT    126
TABLE 57    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    127
TABLE 58    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    127
TABLE 59    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    128
TABLE 60    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    128
TABLE 61    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    129
TABLE 62    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)    129
TABLE 63    EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    130
12.3.1    GERMANY    130
12.3.1.1    Increasing demand for self-injection devices to drive market demand    130
TABLE 64    GERMANY: MACROECONOMIC INDICATORS    131
TABLE 65    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    131
TABLE 66    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    132
TABLE 67    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    132
TABLE 68    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    133
TABLE 69    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)    133
TABLE 70    GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    134
12.3.2    FRANCE    134
12.3.2.1    High prevalence of age-related chronic diseases and infectious diseases to drive market growth    134
TABLE 71    FRANCE: MACROECONOMIC INDICATORS    135
TABLE 72    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    135
TABLE 73    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    136
TABLE 74    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    136
TABLE 75    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    137
TABLE 76    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)    137
TABLE 77    FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    138
12.3.3    UK    138
12.3.3.1    Increasing incidence of chronic diseases and rising prevalence of obesity to drive market growth    138
TABLE 78    UK: MACROECONOMIC INDICATORS    139
TABLE 79    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    139
TABLE 80    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    140
TABLE 81    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    140
TABLE 82    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2019–2026 (USD MILLION)    141
TABLE 83    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    141
TABLE 84    UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    142
12.3.4    ITALY    142
12.3.4.1    Increasing geriatric population and prevalence of chronic diseases to drive market growth    142
TABLE 85    ITALY: MACROECONOMIC INDICATORS    143
TABLE 86    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    143
TABLE 87    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    144
TABLE 88    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    144
TABLE 89    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    145
TABLE 90    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    145
TABLE 91    ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    146
12.3.5    SPAIN    146
12.3.5.1    Increasing prevalence of chronic diseases and technological advancement to drive market growth    146
TABLE 92    SPAIN: MACROECONOMIC INDICATORS    147
TABLE 93    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    147
TABLE 94    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    148
TABLE 95    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    148
TABLE 96    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    149
TABLE 97    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    149
TABLE 98    SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    150
12.3.6    REST OF EUROPE    150
TABLE 99    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    150
TABLE 100    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    151
TABLE 101    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    151
TABLE 102    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    152
TABLE 103    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    152
TABLE 104    ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    153
12.4    ASIA PACIFIC    153
FIGURE 31    ASIA PACIFIC: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT    154
TABLE 105    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    155
TABLE 106    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    155
TABLE 107    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    155
TABLE 108    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    156
TABLE 109    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    156
TABLE 110    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    157
TABLE 111    APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    157
12.4.1    JAPAN    158
12.4.1.1    Increasing geriatric population and higher adoption advance technology to drive market growth    158
TABLE 112    JAPAN: MACROECONOMIC INDICATORS    158
TABLE 113    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
 2019–2026 (USD MILLION)    158
TABLE 114    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    159
TABLE 115    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    159
TABLE 116    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    160
TABLE 117    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    160
TABLE 118    JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    161
12.4.2    CHINA    161
12.4.2.1    Growing prevalence of lifestyle-related and chronic diseases to drive market growth    161
TABLE 119    CHINA: MACROECONOMIC INDICATORS    162
TABLE 120    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    162
TABLE 121    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    163
TABLE 122    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    163
TABLE 123    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    164
TABLE 124    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    164
TABLE 125    CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    165
12.4.3    INDIA    165
12.4.3.1    Collaboration with key players in needle-free injections to drive market growth    165
TABLE 126    INDIA: MACROECONOMIC INDICATORS    166
TABLE 127    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    166
TABLE 128    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    167
TABLE 129    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    167
TABLE 130    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    168
TABLE 131    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION)    168
TABLE 132    INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    169
12.4.4    REST OF ASIA PACIFIC    169
TABLE 133    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    170
TABLE 134    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    170
TABLE 135    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    170
TABLE 136    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    171
TABLE 137    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)    171
TABLE 138    ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION)    172
12.5    LATIN AMERICA    172
TABLE 139    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    172
TABLE 140    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION)    173
TABLE 141    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION)    173
TABLE 142    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
 BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    174
TABLE 143    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)    174
TABLE 144    LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)    175
12.6    MIDDLE EAST & AFRICA    175
12.6.1    SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TO DRIVE MARKET GROWTH    175
TABLE 145    AFRICA: MACROECONOMIC INDICATORS    176
TABLE 146    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
 BY PRODUCT, 2019–2026 (USD MILLION)    176
TABLE 147    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION)    177
TABLE 148    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)    177
TABLE 149    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)    178
TABLE 150    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)    178
TABLE 151    MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
 BY END USER, 2019–2026 (USD MILLION)    179
13    COMPETITIVE LANDSCAPE    180
13.1    OVERVIEW    180
13.2    KEY PLAYER STRATEGIES/RIGHT TO WIN    180
13.3    REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE NEEDLE-FREE INJECTION SYSTEM MARKET    181
13.4    NEEDLE-FREE INJECTION SYSTEM MARKET RANKING    181
13.5    COMPANY EVALUATION QUADRANT    183
FIGURE 32    NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX, 2020    183
13.5.1    STARS    184
13.5.2    PERVASIVE PLAYERS    184
13.5.3    EMERGING LEADERS    184
13.5.4    PARTICIPANTS    184
13.6    COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS    185
FIGURE 33    NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UP    185
13.6.1    PROGRESSIVE COMPANIES    186
13.6.2    DYNAMIC COMPANIES    186
13.6.3    STARTING BLOCKS    186
13.6.4    RESPONSIVE COMPANIES    186
13.7    COMPETITIVE BENCHMARKING    186
13.7.1    OVERALL COMPANY FOOTPRINT    186
TABLE 153    OVERALL COMPANY FOOTPRINT (25 COMPANIES)    186
TABLE 154    COMPANY FOOTPRINT: BY-PRODUCTS (25 COMPANIES)    188
TABLE 155    COMPANY FOOTPRINT: BY TECHNOLOGY (25 COMPANIES)    189
TABLE 156    COMPANY FOOTPRINT: BY TYPE (25 COMPANIES)    190
TABLE 157    COMPANY FOOTPRINT: BY SITE OF DELIVERY (25 COMPANIES)    191
TABLE 158    COMPANY FOOTPRINT: BY APPLICATION (25 COMPANIES)    192
13.8    COMPETITIVE SCENARIO    193
13.8.1    PRODUCT LAUNCHES & APPROVALS    193
13.8.2    DEALS    193
TABLE 159    DEALS (2019–2021)    193
13.8.3    EXPANSIONS    194
TABLE 160    EXPANSIONS (2018)    194
14    COMPANY PROFILES    195
14.1    KEY PLAYERS    195
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1    PHARMAJET    195
TABLE 161    PHARMAJET: BUSINESS OVERVIEW    195
14.1.2    PORTAL INSTRUMENTS    198
TABLE 162    PORTAL INSTRUMENTS: BUSINESS OVERVIEW    198
14.1.3    MEDICAL INTERNATIONAL TECHNOLOGY INC.(MIT)    200
TABLE 163    MEDICAL INTERNATIONAL TECHNOLOGY INC: BUSINESS OVERVIEW    200
14.1.4    NUGEN MEDICAL DEVICES    202
TABLE 164    NUGEN MEDICAL DEVICES: BUSINESS OVERVIEW    202
14.1.5    CROSSJECT SA    204
TABLE 165    CROSSJECT SA: BUSINESS OVERVIEW    204
14.1.6    BIOJECT MEDICAL TECHNOLOGIES INC. (ACQUIRED BY INOVIO PHARMACEUTICALS, INC.)    206
TABLE 166    BIOJECT MEDICAL TECHNOLOGIES INC.: BUSINESS OVERVIEW    206
14.1.7    ANTARES PHARMA    207
TABLE 167    ANTARES PHARMA: BUSINESS OVERVIEW    207
FIGURE 34    ANTARES PHARMA: COMPANY SNAPSHOT    208
14.1.8    INJEX PHARMA GMBH    210
TABLE 168    INJEX PHARMA GMBH: BUSINESS OVERVIEW    210
14.1.9    NATIONAL MEDICAL PRODUCTS, INC.    211
TABLE 169    NATIONAL MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW    211
14.1.10    ZEALAND PHARMA A/S.    212
TABLE 170    ZEALAND PHARMA A/S: BUSINESS OVERVIEW    212
14.2    OTHER PLAYERS    213
14.2.1    PENJET CORPORATION    213
TABLE 171    PENJET CORPORATION: BUSINESS OVERVIEW    213
14.2.2    ENESI PHARMA LIMITED    214
14.2.3    INTEGRIMEDICAL LLC    216
TABLE 173    INTEGRIMEDICAL LLC: BUSINESS OVERVIEW    216
14.2.4    AKRA DERMOJET    217
TABLE 174    AKRA DERMOJET: BUSINESS OVERVIEW    217
14.2.5    D'ANTONIO CONSULTANTS INTERNATIONAL, INC.    218
TABLE 175    D'ANTONIO CONSULTANTS INTERNATIONAL, INC: BUSINESS OVERVIEW    218
14.2.6    BASCO INDIA    219
TABLE 176    BASCO INDIA: BUSINESS OVERVIEW    219
14.2.7    MIKA MEDICAL CO.    220
TABLE 177    MIKA MEDICAL CO.: BUSINESS OVERVIEW    220
14.2.8    MADA MEDICAL PRODUCTS, INC.    221
TABLE 178    MADA MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW    221
14.2.9    VAXXAS    222
TABLE 179    VAXXAS: BUSINESS OVERVIEW    222
14.2.10    GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD    223
TABLE 180    GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD: BUSINESS OVERVIEW    223
14.2.11    QUINOVARE    224
TABLE 181    QUINOVARE: BUSINESS OVERVIEW    224
14.2.12    TAPEMARK    225
TABLE 182    TAPEMARK: BUSINESS OVERVIEW    225
14.2.13    THERAJECT    226
TABLE 183    THERAJECT: BUSINESS OVERVIEW    226
14.2.14    ZOSANO PHARMA    227
TABLE 184    ZOSANO PHARMA: BUSINESS OVERVIEW    227
14.2.15    CORIUM    228
TABLE 185    CORIUM: BUSINESS OVERVIEW    228
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15    APPENDIX    229
15.1    DISCUSSION GUIDE    229
15.2    INDUSTRY INSIGHTS    234
15.3    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    235
15.4    AVAILABLE CUSTOMIZATIONS    237
15.5    RELATED REPORTS    237
15.6    AUTHOR DETAILS    238"